Clinical Trial Update: An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent/ Advanced Stage Endometrial Cancer Patients [Phase 2]

View source ↗

Summary

Phase II open-label trial evaluating niraparib in combination with anti-PD1 antibody for recurrent/advanced endometrial cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Anti-PD1 antibody
• Niraparib (Niraparib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Recurrent/ Advanced Stage Endometrial Cancer Patients | Phase 2 | Status: UNKNOWN